Skip to main content
SpringerLink
Log in

Gichtmittel

  • Chapter
  • First Online:
Arzneiverordnungs-Report 2020

  • 2964 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Literatur

  • Arzneimittelkommission der deutschen Ärzteschaft (2017) Akzidentelle Überdosierung von Colchicin mit Todesfolge. Dtsch Arztebl 114:A96–97

    Google Scholar 

  • Azevedo VF, Buiar PG, Giovanella LH, Severo CR, Carvalho M (2014) Allopurinol, benzbromarone, or a combination in treating patients with gout: analysis of a series of outpatients. Int J Rheumatol. https://doi.org/10.1155/2014/263720

    Article  PubMed  PubMed Central  Google Scholar 

  • Dalbeth N, Merriman TR, Stamp LK (2016) Gout. Lancet 388:2039–2052

    Article  CAS  Google Scholar 

  • Diesinger C, Schriever J (2017) Colchicin – gut informieren, vorsichtig dosieren. Bulletin zur Arzneimittelsicherheit, Bd. 4, S 15–23

    Google Scholar 

  • Fachinfo (2018) Fachinformation Allopurinol ratiopharm. https://www.fachinfo.de/suche/fi/000073

  • Faruque LI, Ehteshami-Afshar A, Wiebe N, Tjosvold L, Homik J, Tonelli M (2013) A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout. Semin Arthritis Rheum 43:367–375

    Article  CAS  PubMed  Google Scholar 

  • FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, Gelber AC, Harrold LR, Khanna D, King C, Levy G, Libbey C, Mount D, Pillinger MH, Rosenthal A, Singh JA, Sims JE, Smith BJ, Wenger NS, Bae SS, Danve A, Khanna PP, Kim SC, Lenert A, Poon S, Qasim A, Sehra ST, Sharma TSK, Toprover M, Turgunbaev M, Zeng L, Zhang MA, Turner AS, Neogi T (2020) American College of Rheumatology guideline for the management of gout. Arthritis Care Res 72:744–760

    Google Scholar 

  • Janssens H, Lucassen P, van de Laar F, Janssen M, van de Lisdonk E (2008) Systemic corticosteroids for acute gout. Cochrane Database Syst Rev 2008(2):CD5521

    Google Scholar 

  • Lin KC, Lin HY, Chou P (2000) Community based epidemiological study on hyperuricemia and gout in Kin-Hou. J Rheumatol 27:1045–1050

    CAS  PubMed  Google Scholar 

  • Love BL, Barrons R, Veverka A, Snider KM (2010) Urate-lowering therapy for gout: focus on febuxostat. Pharmacotherapy 30:594–608

    Article  CAS  PubMed  Google Scholar 

  • NN (2014) Bei asymptomatischer Hyperurikämie wird zu häufig Allopurinol verordnet. Arzneimittelbrief 48:46–47

    Google Scholar 

  • Pasina L, Brucato AL, Djade CD, Di Corato P, Ghindoni S, Tettamanti M, Franchi C, Salerno F, Corrao S, Marcucci M, Mannucci PM, Nobili A (2014) Inapprobiate prescription of allopurinol and febuxostat and risk of adverse events in the elderly: results from the REPOSI registry. Eur J Clin Pharmacol 70:1495–1503

    Article  CAS  PubMed  Google Scholar 

  • Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, Coyfish M, Guillo S, Jansen TL, Janssens H, Lioté F, Mallen C, Nuki G, Perez-Ruiz F, Pimentao J, Punzi L, Pywell T, So A, Tausche AK, Uhlig T, Zavada J, Zhang W, Tubach F, Bardin T (2017) 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 76:29–42

    Article  CAS  PubMed  Google Scholar 

  • Rote-Hand-Brief zu Adenuric® (Febuxostat) und anderen febuxostathaltigen Arzneimitteln: Erhöhtes Risiko für kardiovaskulär bedingte Mortalität und Gesamtmortalität. https://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RHB/2019/rhb-febuxostat.pdf;jsessionid=F9D0C6D192F65578CDDA5B27ED0C9CF5.1_cid344?__blob=publicationFile&v=4

  • Shiozawa A, Szabo SM, Bolzani A, Cheung A, Choi HK (2017) Serum uric acid and the risk of incident and recurrent gout: a systematic review. J Rheumatol 44:388–396

    Article  CAS  PubMed  Google Scholar 

  • Singh JA, Cleveland JD (2019) Comparative effectiveness of allopurinol and febuxostat for the risk of atrial fibrillation in the elderly: a propensity-matched analysis of Medicare claims data. Eur Heart J 40:3046–3054

    Article  PubMed  Google Scholar 

  • Sundy JS (2010) Progress in the pharmacotherapy of gout. Curr Opin Rheumatol 22:188–193

    Article  CAS  PubMed  Google Scholar 

  • Suresh E, Das P (2012) Recent advances in management of gout. QJM 105:407–417

    Article  CAS  PubMed  Google Scholar 

  • Tayar JH, Lopez-Olivo MA, Suarez-Almazor ME (2012) Febuxostat for treating chronic gout. Cochrane Database Syst Rev 2012(11):CD8653

    PubMed Central  Google Scholar 

  • Van Echteld I, Wechalekar MD, Schlesinger N, Buchbinder R, Aletaha D (2014) Colchicine for acute gout. Cochrane Database Syst Rev 2014(8):CD6190

    Google Scholar 

  • White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L (2018) Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med 378:1200–1210

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Pharmakologie, Klinikum Bremen-Mitte, St.-Jürgen-Straße 1, 28205, Bremen, Deutschland

    Prof. Dr. med. Bernd Mühlbauer

  2. Institut für Pharmakologie und Toxikologie der Universität Göttingen, Robert-Koch-Straße 40, 37075, Göttingen, Deutschland

    Prof. Dr. med. Gerhard Schmidt

Authors
  1. Prof. Dr. med. Bernd Mühlbauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Gerhard Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bernd Mühlbauer .

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Heidelberg, Baden-Württemberg, Germany

    Ulrich Schwabe

  2. Arzneimittelkommission der deutschen Ärzteschaft, Berlin, Berlin, Germany

    Wolf-Dieter Ludwig

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Der/die Herausgeber bzw. der/die Autor(en), exklusiv lizenziert durch Springer-Verlag GmbH, DE, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Mühlbauer, B., Schmidt, G. (2020). Gichtmittel. In: Schwabe, U., Ludwig, WD. (eds) Arzneiverordnungs-Report 2020. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-62168-4_25

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-62168-4_25

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-62167-7

  • Online ISBN: 978-3-662-62168-4

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation